Mr. Zaheed Mawani reports

DRI HEALTHCARE COMMENTS ON JUVMO'S (TAVAPADON) FDA APPROVAL

DRI Healthcare Trust has commented on the U.S. Food and Drug Administration's recently announced approval of Juvmo (tavapadon) for the treatment of motor symptoms that occur in Parkinson's disease. Juvmo (tavapadon) is a novel selective dopamine D1/D5 receptor partial agonist developed as a once-daily oral treatment for Parkinson's disease, for use both with and without levodopa.

DRI Healthcare previously announced that it has entered into certain purchase agreements to acquire certain royalty participation rights in U.S. net sales of Juvmo (tavapadon) from funds managed by Bain Capital and NovaQuest Capital Management. DRI Healthcare will pay an aggregate purchase price of $316-million (U.S.) at closing, financed through a combination of cash on hand and borrowings under its credit facility. Closing is subject to the satisfaction of certain customary closing conditions and is expected to occur on Sept. 29, 2026.

Transaction terms

Under the terms of the purchase agreements, DRI Healthcare will be entitled to four annual fixed payments of $23.4-million (U.S.) on or before each of the first four anniversaries of FDA approval, commencing on Sept. 25, 2027. DRI Healthcare will also be entitled to receive tiered royalty payments on annual U.S. net sales of Juvmo (tavapadon), at combined tiered, mid-single-digit to low-double-digit royalty rates, and certain sales milestone payments upon first reaching certain cumulative U.S. net sales thresholds. Aggregate receipts to DRI Healthcare under the acquired payment rights will be subject to a contractual hard cap of $437.5-million (U.S.).

About Parkinson's disease

Parkinson's disease is a progressive neurological and chronic neurological disorder affecting more than 10 million people globally. It is caused by the loss of dopamine-producing neurons in a region of the brain called the substantia nigra. By the time motor symptoms become apparent, 60 to 80 per cent of those neurons have already been lost. PD presents with both motor and non-motor symptoms. Motor symptoms include tremor, limb rigidity, slowness of movement, and problems with balance and gait. Non-motor symptoms, which patients often find equally debilitating, include depression, anxiety, sleep disorders, cognitive changes and loss of smell. Symptoms progress at different rates and vary from person to person. There is no cure, and, while treatments can improve quality of life, none have been shown to slow or halt disease progression.

About DRI Healthcare Trust

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Since its founding in 1989, it has deployed more than $3.0-billion, acquiring more than 75 royalties on 50-plus drugs, including Eylea, Keytruda, Lumvoa, Orserdu, Remicade, Spinraza, Stelara, Vonjo and Zytiga. DRI Healthcare's units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol DHT.UN and in U.S. dollars under the symbol DHT.U.

We seek Safe Harbor.